UBS Maintains Neutral on American Well, Lowers Price Target to $0.6
$AMWL
Business Services
Consumer Discretionary
UBS analyst Kevin Caliendo maintains American Well (NYSE:AMWL) with a Neutral and lowers the price target from $1.5 to $0.6.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/3/2023 | $5.00 → $2.50 | Overweight → Equal-Weight | Morgan Stanley |
| 3/23/2023 | $5.00 → $2.50 | Outperform → Market Perform | TD Cowen |
| 2/27/2023 | $5.00 → $3.50 | Overweight → Neutral | Piper Sandler |
| 1/4/2023 | $4.20 | Neutral → Buy | BofA Securities |
| 9/7/2022 | $5.00 | Hold | Truist |
| 4/14/2022 | $6.00 | Buy | Guggenheim |
| 4/1/2022 | $5.00 | Neutral | Credit Suisse |
| 2/28/2022 | $6.00 → $4.00 | Equal-Weight | Wells Fargo |
UBS analyst Kevin Caliendo maintains American Well (NYSE:AMWL) with a Neutral and lowers the price target from $1.5 to $0.6.
SC 13G/A - American Well Corp (0001393584) (Subject)
SC 13G - American Well Corp (0001393584) (Subject)
SC 13G - American Well Corp (0001393584) (Subject)
144 - American Well Corp (0001393584) (Subject)
S-8 - American Well Corp (0001393584) (Filer)
8-K - American Well Corp (0001393584) (Filer)
Morgan Stanley downgraded Amwell from Overweight to Equal-Weight and set a new price target of $2.50 from $5.00 previously
TD Cowen downgraded Amwell from Outperform to Market Perform and set a new price target of $2.50 from $5.00 previously
Piper Sandler downgraded Amwell from Overweight to Neutral and set a new price target of $3.50 from $5.00 previously
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, today announced Mark Hirschhorn will become Amwell Chief Financial Officer (CFO) effective Oct. 21, succeeding Robert "Bob" Shepardson, who has been in the role since 2021. Hirschhorn will oversee Amwell's financial operations, enterprisewide optimization and capital allocation activities, and will play a meaningful leadership role in guiding the company's strategy to support its long-term growth objectives and enhance shareholder value. Hirschhorn is a healthcare technology industry leader, with over three decades of experience in financial and strategic operations, having served in senior executiv
Boston, June 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, today announces the appointment of Ricky Goldwasser to the company's Board of Directors, effective June 13. "Ricky brings to our board a deep financial background that makes her an invaluable addition as we focus on Amwell's path to profitability. Ricky's strong voice coupled with her impressive track record will help guide Amwell as we strive for greater efficiencies, optimized cash flow and profitable growth, while remaining committed to enabling our clients to achieve their goals. We are pleased to welcome Ricky to the team," said Ido Schoenberg, M.D., CEO and chairman, Amwell. Ms. Gol
ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board's Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. "I am happy to welcome Kathy to the Board as Axogen is approaching an exciting inflection point in its journ
BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the third quarter ended Sept. 30, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the third quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Oct. 30. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants or 1-646-960-0306 for international participants, referencing conference ID number 7830032. A replay of the call will
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, will report third quarter 2024 operating results on Wednesday, Oct. 30. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days. About Amwell Amwell is a leading hybrid care, delivery enablement platfor
Boston, July 31, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the second quarter ended June 30, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the second quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Wednesday, July 31. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants or 1-646-960-0306 for international participants, referencing conference ID number 7830032. A replay o
4 - American Well Corp (0001393584) (Issuer)
4 - American Well Corp (0001393584) (Issuer)
4 - American Well Corp (0001393584) (Issuer)
BOSTON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, today announced that, on November 4, 2024, it made a grant of restricted stock units ("RSUs") covering 254,227 shares of its Class A common stock to Mark Hirschhorn. The grant was offered as material inducement to Mr. Hirschhorn's employment as Amwell's chief financial officer. The RSUs become vested as follows, subject to Mr. Hirschhorn's continued employment through each vesting date, except as noted below: 25% of the RSUs vested on the grant date, and the remaining 75% of the RSUs will vest in substantially equal quarterly installments over a three-year period, starting on the one-year anniversary o
BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the third quarter ended Sept. 30, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the third quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Oct. 30. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants or 1-646-960-0306 for international participants, referencing conference ID number 7830032. A replay of the call will
BOSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, announced company leaders will participate in several upcoming investor conferences. Ido Schoenberg, M.D., Amwell chairman and chief executive officer, and Mark Hirschhorn, Amwell chief financial officer, will participate in fireside chats or one-on-one meetings at these events: Nov. 12: UBS Global Healthcare Conference in Palos Verdes, Calif. The fireside chat is at 8:45 a.m. PT.Nov. 20: Needham 4th Annual Consumer Tech Conference. Virtual one-on-one meetings throughout the day.Nov. 25: The BTIG Virtual Health Forum. Virtual one-on-one meetings throughout the day.Dec. 4: The Piper Sandler 36th Annual